Alaa Embaby

Dr. Alaa Embaby


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Gynecologic Oncology
Verified
Journal Article
Closed access
AEAlaa Embaby
Alaa Embaby
JKJoachim Kutzera
Joachim Kutzera
JGJill J. Geenen
Jill J. Geenen
DPDick Pluim
Dick Pluim
IHIngrid Hofland
Ingrid Hofland
FOFrans L. Opdam
Frans L. Opdam

13 May 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
AEAlaa Embaby
Alaa Embaby
SHSanne C.F.A. Huijberts
Sanne C.F.A. Huijberts
LWLiqin Wang
Liqin Wang
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
HRHilde Rosing
Hilde Rosing
SWSofie Wilgenhof
Sofie Wilgenhof
Purpose: The development of resistance limits the clinical benefit of BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600-mutated melanoma. It has been shown that short-term treatment (14 days) with vorinostat was able to initiate apoptosis of resistant tumor cells. We aimed to assess the antitumor activity of sequential treatment with vorinostat following BRAFi/MEKi in patients with BRAFV600-mutated melanoma who progressed after initial response to BRAFi/MEKi. Patients and Methods: Patients with BRAFi/MEKi-resistant BRAFV600-mutated melanoma were treated with vorinostat 360 mg once daily for 14 days followed by BRAFi/MEKi. The primary endpoint was an objective response rate of progressive lesions of at least 30% according to Response Evaluation Criteria in Solid Tumors 1.1. Secondary endpoints included progression-free survival, overall survival, safety, pharmacokinetics of vorinostat, and translational molecular analyses using ctDNA and tumor biopsies. Results: Of the 26 patients with progressive BRAFi/MEKi-resistant BRAFV600-mutated melanoma receiving treatment with vorinostat, 22 patients were evaluable for response. The objective response rate was 9%, with one complete response for 31.2 months and one partial response for 14.9 months. Median progression-free survival and overall survival were 1.4 and 5.4 months, respectively. Common adverse events were fatigue (23%) and nausea (19%). ctDNA analysis showed emerging secondary mutations in NRAS and MEK in eight patients at the time of BRAFi/MEKi resistance. Elimination of these mutations by vorinostat treatment was observed in three patients. Conclusions: Intermittent treatment with vorinostat in patients with BRAFi/MEKi-resistant BRAFV600-mutated melanoma is well tolerated. Although the primary endpoint of this study was not met, durable antitumor responses were observed in a minority of patients (9%).

1 March 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
AEAlaa Embaby
Alaa Embaby
KHKimberley M. Heinhuis
Kimberley M. Heinhuis
NINikki S. Ijzerman
Nikki S. Ijzerman
AKAnne Miek Koenen
Anne Miek Koenen
SKStephanie van der Kleij
Stephanie van der Kleij
NSNeeltje Steeghs
Neeltje Steeghs

15 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
AEAlaa Embaby
Alaa Embaby
LMLisanne van Merendonk
Lisanne van Merendonk
NSNeeltje Steeghs
Neeltje Steeghs
JBJos Beijnen
Jos Beijnen
AHAlwin Huitema
Alwin Huitema
Beta-blockers are currently studied to improve therapeutic options for patients with angiosarcoma. However, most of these patients have no cardiovascular co-morbidity and it is therefore crucial to discuss the most optimal pharmacological properties of beta-blockers for this population. To maximize the possible effectiveness in angiosarcoma, the use of a non-selective beta-blocker is preferred based on in vitro data. To minimize the risk of cardiovascular adverse events a beta-blocker should ideally have intrinsic sympathomimetic activity or vasodilator effects, e.g. labetalol, pindolol or carvedilol. However, except for one case of carvedilol, only efficacy data of propranolol is available. In potential follow-up studies labetalol, pindolol or carvedilol can be considered to reduce the risk of cardiovascular adverse events.

11 May 2024 in Toxicology Reports
Verified
Journal Article
Open access
AEAlaa Embaby
Alaa Embaby
MBMarjorie Balai
Marjorie Balai
EFEric J.F. Franssen
Eric J.F. Franssen
Intentional overdose with insulin preparations is rare. However, fatal consequences due to severe hypoglycemia could occur. Postmortem toxicology screening of insulin is a challenge, given the chemical characteristics of this protein and the difficulty of distinguishing between endogenous and exogenous insulin in blood. Here, we describe two cases of patients with diabetes using insulin and oral anti-diabetics. The main question in both cases was whether or not disturbance in glucose metabolism contributed to death. In case A, there was strong evidence that self-poisoning with insulin and subsequent hypoglycemia caused the death. However, this could not be confirmed due to lack of adequate forensic toxicology tests. In case B, no hypoglycemia was observed. Though, compared with case A, additional forensic examination was performed to investigate whether glycemic disturbances could have contributed to the death. In this report, we focus on the most appropriate analytical methods for the detection of exogenous insulin in the human body and give recommendations for toxicology testing of glucose levels and insulin in postmortem specimens.

1 August 2024
Verified
Other
Open access
PDF file
AEAlaa Embaby
Alaa Embaby
SHSanne C.F.A. Huijberts
Sanne C.F.A. Huijberts
LWLiqin Wang
Liqin Wang
RORodrigo Leite de Oliveira
Rodrigo Leite de Oliveira
HRHilde Rosing
Hilde Rosing
SWSofie Wilgenhof
Sofie Wilgenhof
Supplementary Fig. S1. Spider plot showing the best response and change in size of progressive target lesions per patient during treatment.